Tuberculosis treatment is like a marathon that many patients struggle to finish because the medicine makes them feel sick. This project is building a 'support team' for the body's immune system to help the antibiotics work faster and better. By using things like smart antibodies and vaccines, they aim to cut down the time patients spend on medication and stop the bacteria from becoming resistant.
Tuberculosis treatment is too long and toxic, leading to poor patient adherence and the rise of antibiotic-resistant strains. There is an urgent need for therapies that shorten treatment time and improve cure rates.
A preclinical pipeline including validated human lung organoids and a selection of 11 compounds (monoclonal antibodies, vaccines, and small molecules) for adjunctive TB therapy.
If you are a drug developer dealing with the high failure rate of long-term TB antibiotic regimens — this project developed a pipeline of immunomodulatory compounds and monoclonal antibodies that can serve as adjuncts to shorten treatment duration.
If you are a vaccine manufacturer dealing with the need for therapeutic rather than just preventative options — this project developed therapeutic vaccines tested in human lung organoids to improve patient outcomes.
If you are a biomarker R&D firm dealing with the lack of efficacy predictors for TB treatments — this project developed in silico and in vitro models to optimize the selection of immunotherapies with the highest clinical potential.
Based on available project data, there is no information regarding the cost or pricing of the developed therapies.
The project includes an industrial partner, GSK, involved in drug and vaccine R&D, though specific industrial scaling plans are not detailed in the summary.
Based on available project data, specific IP or licensing terms are not mentioned, but the project involves a consortium of 11 partners including two Product Development Partnerships.
The project runs from 2023-06-01 to 2027-05-31, with a goal to progress two interventions to preclinical proof-of-concept in non-human primates within this period.
The strategy is to combine current standard-of-care antibiotics with new immunotherapies as an adjunctive treatment to reduce toxicity and duration.
The consortium is highly specialized, consisting of 11 partners across 7 countries. It balances academic research (5 universities, 4 research institutes) with strategic industry and non-profit expertise, including GSK and two Product Development Partnerships (TBVI, TB-Alliance). The 9% industry ratio indicates a project heavily focused on early-stage R&D and preclinical validation rather than immediate commercial rollout.
Contact Stichting Tuberculosis Vaccine Initiative (NL)
Contact us to explore licensing opportunities for the 11 selected TB immunotherapy compounds.
